Trials / Completed
CompletedNCT00660764
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile who had not been treated with cholesterol lowering drugs at least in the past three months. Also set-up costs of rosuvastatin treatment and proportional changes in LDL-C and high-density lipoprotein cholesterol (HDL-C) were studied.
Conditions
- Hypercholesterolemia
- Coronary Heart Disease
- Peripheral Vascular Disease
- Cerebrovascular Accident
- Diabetes
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rosuvastatin | Oral |
Timeline
- Start date
- 2003-05-01
- Completion
- 2005-04-01
- First posted
- 2008-04-17
- Last updated
- 2009-03-16
Source: ClinicalTrials.gov record NCT00660764. Inclusion in this directory is not an endorsement.